Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.51 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 4/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502110 | 0.90 | SRC (0.51) | SRCFGFR1BRPF1EGFRFGFR2 | |
| SCHEMBL4566795 | 0.86 | SRC (0.55) | SRCFGFR1BRPF1EGFRFGFR2 | |
| SCHEMBL24665079 | 0.81 | FGFR1 (0.45) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL4427123 | 0.81 | FGFR1 (0.46) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL24665058 | 0.80 | FGFR1 (0.50) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL24665006 | 0.79 | FGFR1 (0.47) | SRCFGFR1EGFRABL1PDGFRB | |
| SCHEMBL24666763 | 0.78 | FGFR1 (0.46) | SRCFGFR1EGFRABL1PDGFRB | |
| SCHEMBL29977716 | 0.78 | FGFR1 (0.70) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL24665042 | 0.78 | SRC (0.54) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL24666947 | 0.78 | FGFR1 (0.70) | SRCFGFR1EGFRFGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| EP-1673343-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-10 | — | — | EP | disclosed |
| EP-1673343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-06-28 | — | — | EP | disclosed |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-08-25 | — | — | US | disclosed |
| WO-2005034869-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | FYN, LCK, SRC | SRC 3/4885FGFR1 76/4885BRPF1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.